ClinicalTrials.gg
TerminatedNCT02245438Updated Sep 19, 2014

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

A Phase 1 interventional study of Tipranavir low dose and Tipranavir high dose in Healthy, sponsored by Boehringer Ingelheim. Terminated. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Study to characterize the effects of two dose combinations of Tipranavir (TPV)/Ritonavir (RTV) (TPV 750 mg/RTV 200 mg and TPV 500 mg/RTV 100 mg), administered twice-daily, on the pharmacokinetics of Norethindrone-Ethinyl Estradiol (NET/EE) 1 mg/ 0.035 mg administered as a single dose.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects between 18 and 50 years of age inclusive
  2. A (BMI) between 18 and 29 kg/m2
  3. Signed prior to trial participation
  4. Ability to swallow numerous large capsules without difficulty
  5. Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity is less than or equal to Grade 1, based on the AIDS Clinical Trials Group Grading Scale. All abnormal laboratory values greater than Grade 1 are subject to approval by the trial clinical monitor.
  6. Acceptable medical history, physical examination and , and chest X-ray (if not conducted within the last 12 months) are required prior to entering the treatment phase of the study
  7. Willingness to abstain from alcohol for 48 hours prior to Study Day 0 and abstain from alcohol for the duration of the study. In addition, red wine must not have been ingested within 5 days prior to Day 0 (Visit 2)
  8. Willingness to abstain from ingesting grapefruit, grapefruit juice, or products containing grapefruit juice, within 10 days before Day 0, Visit 2 and for the duration of the study
  9. Willingness to abstain from ingesting Seville oranges, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 5 days of Day 0, Visit 2 and for the duration of the study
  10. Willingness to abstain from over the counter herbal medications for the duration of the study
  11. Reasonable probability for completion of the study

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are of who:

    • Have positive serum beta-human chorionic gonadotropin at Visit 1, or on Day 0 or Day 1
    • Have not been using a barrier method for at least 3 months prior to Visit 3 (Day 1)
    • Are not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during the trial and 30 days after completion/termination
    • Are breast-feeding
  2. Participation in another trial with an medicine within 30 days prior to Day 0 (Visit 2)
  3. Use of any medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
  4. Use of any other pharmacological contraceptive (including oral, patch or injectable contraceptives) for 1 month prior to study initiation and for the duration of the study
  5. Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
  6. History of central nervous system (CNS), gastrointestinal, hepatic, or renal disorders within the past sixty (60) days. Subjects will be excluded for these disorders greater than sixty days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
  7. History of thrombotic disease
  8. History of migraine headache
  9. Have serological evidence of or C virus
  10. Have serological evidence of exposure to
  11. Recent history of alcohol or substance abuse (within 6 months of study period)
  12. Cigarette smoking (greater than 10 cigarettes per day)
  13. Blood or plasma donations within 30 days prior to Day 0 (Visit 2) or during the trial.
  14. Subjects with a seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/min or >90 beats/min. For subjects with a resting heart rate below 50, due to a high fitness level, the investigator may discuss exclusion with the medical monitor on a case-by-case basis
  15. Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering Tipranavir, Ritonavir or NET/EE to the subject
  16. Subjects who have had an acute illness within 2 weeks prior to Day 0 (Visit 2)
  17. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day 0,(Visit 2) or who are currently taking any prescription drug that, in the opinion of the investigator in consultation with the clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
  18. Known to TPV, RTV, or NET/EE
  19. Inability to comply with the protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    TPV/RTV low dose

    Drug: Tipranavir low dose · Drug: Ritonavir low dose · Drug: Norethindrone-Ethinyl Estradiol

  • Experimental
    TPV/RTV high dose

    Drug: Tipranavir high dose · Drug: Ritonavir high dose · Drug: Norethindrone-Ethinyl Estradiol

Interventions

  • DrugTipranavir low dose
  • DrugTipranavir high dose
  • DrugRitonavir low dose

    Also known as: Norvir-SEC®

  • DrugRitonavir high dose

    Also known as: Norvir-SEC®

  • DrugNorethindrone-Ethinyl Estradiol

    Also known as: Ortho®-1/35

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration time curve

    Time frame: up to day 17

  2. Maximum plasma concentration of the analyte

    Time frame: up to day 17

  3. Drug concentration of the analyte in plasma at 12 hours after administration

    Time frame: up to day 17

Secondary outcomes

  1. Oral clearance of the analyte

    Time frame: up to day 17

  2. Time of maximum concentration of the analyte

    Time frame: up to day 17

  3. Apparent terminal half life of the analyte

    Time frame: up to day 17

  4. Number of subjects with adverse events

    Time frame: up to 45 days

  5. Number of subject with clinically relevant changes in laboratory parameters

    Time frame: up to 17 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002 and a primary completion of Jun 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
May 2002
Primary completionActual
Jun 2002
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02245438
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
May 2002
Primary completion
Jun 2002
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion